{"transactions":[{"id":1117770,"issuer":{"id":5216,"kind":"organization","name":"ASSEMBLY BIOSCIENCES, INC."},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-09T20:05:11.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 5, 2026 and (2) the date of the Issuer's 2026 annual meeting of stockholders."}],"balance_after":3500,"derivative":{"exercise_price":15.81,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0000950170-25-083695","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1426800/000095017025083695/ownership.xml","form_type":"4"}},{"id":1136241,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-23T20:30:06.000Z","date":"2025-05-21","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or May 21, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date."}],"balance_after":19000,"derivative":{"exercise_price":0.3202,"expiration_date":"2035-05-20","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001415889-25-014480","document":"form4-05232025_040501.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000141588925014480/form4-05232025_040501.xml","form_type":"4"}},{"id":1481430,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-13T21:04:48.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or June 11, 2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder\nmeeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date."}],"balance_after":19000,"derivative":{"exercise_price":0.709,"expiration_date":"2034-06-10","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001415889-24-016692","document":"form4-06132024_090645.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000141588924016692/form4-06132024_090645.xml","form_type":"4"}},{"id":1497756,"issuer":{"id":5216,"kind":"organization","name":"ASSEMBLY BIOSCIENCES, INC."},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-30T20:05:05.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":2750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) May 29, 2025 and (2) the date of the Issuer's 2025 annual meeting of stockholders."}],"balance_after":2750,"derivative":{"exercise_price":15.06,"expiration_date":"2034-05-29","underlying":"Common Stock","underlying_shares":2750},"source":{"system":"sec-edgar","filing":"0000950170-24-066560","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1426800/000095017024066560/ownership.xml","form_type":"4"}},{"id":1831220,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-12T21:03:44.000Z","date":"2023-07-10","kind":"grant","planned":false,"acquired":true,"shares":14550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or July 10, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date."}],"balance_after":14550,"derivative":{"exercise_price":1.22,"expiration_date":"2033-07-09","underlying":"Common Stock","underlying_shares":14550},"source":{"system":"sec-edgar","filing":"0001209191-23-042103","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000120919123042103/doc4.xml","form_type":"4"}},{"id":1831219,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-12T21:03:44.000Z","date":"2023-07-10","kind":"grant","planned":false,"acquired":true,"shares":4466,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or July 10, 2024, subject to the Reporting Person's continuous service with the Issuer through such vesting date."}],"balance_after":23399,"source":{"system":"sec-edgar","filing":"0001209191-23-042103","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000120919123042103/doc4.xml","form_type":"4"}},{"id":1874686,"issuer":{"id":5216,"kind":"organization","name":"ASSEMBLY BIOSCIENCES, INC."},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-05-30T20:40:10.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) May 25, 2024 and (2) the date of the Issuer's 2024 annual meeting of stockholders."}],"balance_after":20000,"derivative":{"exercise_price":0.972,"expiration_date":"2033-05-23","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-23-032904","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1426800/000120919123032904/doc4.xml","form_type":"4"}},{"id":2253229,"issuer":{"id":5216,"kind":"organization","name":"ASSEMBLY BIOSCIENCES, INC."},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-27T20:23:47.000Z","date":"2022-05-25","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) May 25, 2023 and (2) the date of the Issuer's 2023 annual meeting of stockholders."}],"balance_after":20000,"derivative":{"exercise_price":1.69,"expiration_date":"2032-05-25","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-22-032539","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1426800/000120919122032539/doc4.xml","form_type":"4"}},{"id":2343039,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-09T23:24:37.000Z","date":"2022-03-08","kind":"grant","acquired":true,"shares":29100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to  the option vest monthly over thirty-six (36) months from the vesting commencement date, March 8, 2022, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":29100,"derivative":{"exercise_price":3.08,"expiration_date":"2032-03-07","underlying":"Common Stock","underlying_shares":29100},"source":{"system":"sec-edgar","filing":"0001209191-22-017684","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000120919122017684/doc4.xml","form_type":"4"}},{"id":2343038,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-09T23:24:37.000Z","date":"2022-03-08","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These shares represent RSUs. Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, on March 8, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 8,933 shares acquired by the Reporting Person as of March 8, 2022 as an RSU award."}],"balance_after":18933,"source":{"system":"sec-edgar","filing":"0001209191-22-017684","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000120919122017684/doc4.xml","form_type":"4"}},{"id":2343037,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-09T23:24:37.000Z","date":"2022-03-08","kind":"grant","acquired":true,"shares":8933,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in three equal annual installments on each of March 8, 2023, March 8, 2024, and March 8, 2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":8933,"source":{"system":"sec-edgar","filing":"0001209191-22-017684","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000120919122017684/doc4.xml","form_type":"4"}},{"id":2698719,"issuer":{"id":5216,"kind":"organization","name":"ASSEMBLY BIOSCIENCES, INC."},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-05-24T21:06:16.000Z","date":"2021-05-20","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) May 20, 2022 and (2) the date of the Issuer's 2022 annual meeting of stockholders."}],"balance_after":15000,"derivative":{"exercise_price":4.03,"expiration_date":"2031-05-20","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-21-035412","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1426800/000120919121035412/doc4.xml","form_type":"4"}},{"id":2745461,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-04-19T19:46:08.000Z","date":"2021-04-16","kind":"disposition_to_issuer","acquired":false,"shares":27769,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the \"Merger Agreement\"), by and among the Five Prime Therapeutics, Inc. (the \"Company\"), Amgen Inc. (\"Parent\") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share (\"Common Stock\"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the \"Merger Agreement\"), by and among the Five Prime Therapeutics, Inc. (the \"Company\"), Amgen Inc. (\"Parent\") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share (\"Common Stock\"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not applicable."}],"balance_after":0,"derivative":{"exercise_price":4.47,"underlying":"Common Stock","underlying_shares":27769},"source":{"system":"sec-edgar","filing":"0001209191-21-027417","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919121027417/doc4.xml","form_type":"4"}},{"id":2745460,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-04-19T19:46:08.000Z","date":"2021-04-16","kind":"disposition_to_issuer","acquired":false,"shares":52408,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the \"Merger Agreement\"), by and among the Five Prime Therapeutics, Inc. (the \"Company\"), Amgen Inc. (\"Parent\") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share (\"Common Stock\"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the \"Merger Agreement\"), by and among the Five Prime Therapeutics, Inc. (the \"Company\"), Amgen Inc. (\"Parent\") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share (\"Common Stock\"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not applicable."}],"balance_after":0,"derivative":{"exercise_price":2.8,"underlying":"Common Stock","underlying_shares":52408},"source":{"system":"sec-edgar","filing":"0001209191-21-027417","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919121027417/doc4.xml","form_type":"4"}},{"id":2745459,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-04-19T19:46:08.000Z","date":"2021-04-16","kind":"disposition_to_issuer","acquired":false,"shares":37998,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the \"Merger Agreement\"), by and among the Five Prime Therapeutics, Inc. (the \"Company\"), Amgen Inc. (\"Parent\") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share (\"Common Stock\"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the \"Merger Agreement\"), by and among the Five Prime Therapeutics, Inc. (the \"Company\"), Amgen Inc. (\"Parent\") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share (\"Common Stock\"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not applicable."}],"balance_after":0,"derivative":{"exercise_price":5.23,"underlying":"Common Stock","underlying_shares":37998},"source":{"system":"sec-edgar","filing":"0001209191-21-027417","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919121027417/doc4.xml","form_type":"4"}},{"id":2745458,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-04-19T19:46:08.000Z","date":"2021-04-16","kind":"disposition_to_issuer","acquired":false,"shares":40868,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the \"Merger Agreement\"), by and among the Five Prime Therapeutics, Inc. (the \"Company\"), Amgen Inc. (\"Parent\") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share (\"Common Stock\"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the \"Merger Agreement\"), by and among the Five Prime Therapeutics, Inc. (the \"Company\"), Amgen Inc. (\"Parent\") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share (\"Common Stock\"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not applicable."}],"balance_after":0,"derivative":{"exercise_price":5.31,"underlying":"Common Stock","underlying_shares":40868},"source":{"system":"sec-edgar","filing":"0001209191-21-027417","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919121027417/doc4.xml","form_type":"4"}},{"id":2745457,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-04-19T19:46:08.000Z","date":"2021-04-16","kind":"disposition_to_issuer","acquired":false,"shares":49552,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the \"Merger Agreement\"), by and among the Five Prime Therapeutics, Inc. (the \"Company\"), Amgen Inc. (\"Parent\") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share (\"Common Stock\"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the \"Merger Agreement\"), by and among the Five Prime Therapeutics, Inc. (the \"Company\"), Amgen Inc. (\"Parent\") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share (\"Common Stock\"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not applicable."}],"balance_after":0,"derivative":{"exercise_price":3.94,"underlying":"Common Stock","underlying_shares":49552},"source":{"system":"sec-edgar","filing":"0001209191-21-027417","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919121027417/doc4.xml","form_type":"4"}},{"id":2745456,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-04-19T19:46:08.000Z","date":"2021-04-16","kind":"disposition_to_issuer","acquired":false,"shares":50367,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the \"Merger Agreement\"), by and among the Five Prime Therapeutics, Inc. (the \"Company\"), Amgen Inc. (\"Parent\") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share (\"Common Stock\"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the \"Merger Agreement\"), by and among the Five Prime Therapeutics, Inc. (the \"Company\"), Amgen Inc. (\"Parent\") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share (\"Common Stock\"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not applicable."}],"balance_after":0,"derivative":{"exercise_price":3.23,"underlying":"Common Stock","underlying_shares":50367},"source":{"system":"sec-edgar","filing":"0001209191-21-027417","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919121027417/doc4.xml","form_type":"4"}},{"id":2745455,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-04-19T19:46:08.000Z","date":"2021-04-16","kind":"disposition_to_issuer","acquired":false,"shares":46939,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the \"Merger Agreement\"), by and among the Five Prime Therapeutics, Inc. (the \"Company\"), Amgen Inc. (\"Parent\") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share (\"Common Stock\"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the \"Merger Agreement\"), by and among the Five Prime Therapeutics, Inc. (the \"Company\"), Amgen Inc. (\"Parent\") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share (\"Common Stock\"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not applicable."}],"balance_after":0,"derivative":{"exercise_price":3.99,"underlying":"Common Stock","underlying_shares":46939},"source":{"system":"sec-edgar","filing":"0001209191-21-027417","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919121027417/doc4.xml","form_type":"4"}},{"id":2745454,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-04-19T19:46:08.000Z","date":"2021-04-16","kind":"disposition_to_issuer","acquired":false,"shares":34451,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the \"Merger Agreement\"), by and among the Five Prime Therapeutics, Inc. (the \"Company\"), Amgen Inc. (\"Parent\") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share (\"Common Stock\"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the \"Merger Agreement\"), by and among the Five Prime Therapeutics, Inc. (the \"Company\"), Amgen Inc. (\"Parent\") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share (\"Common Stock\"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not applicable."}],"balance_after":0,"derivative":{"exercise_price":3.79,"underlying":"Common Stock","underlying_shares":34451},"source":{"system":"sec-edgar","filing":"0001209191-21-027417","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919121027417/doc4.xml","form_type":"4"}},{"id":2745453,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-04-19T19:46:08.000Z","date":"2021-04-16","kind":"disposition_to_issuer","acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the \"Merger Agreement\"), by and among the Five Prime Therapeutics, Inc. (the \"Company\"), Amgen Inc. (\"Parent\") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share (\"Common Stock\"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the \"Merger Agreement\"), by and among the Five Prime Therapeutics, Inc. (the \"Company\"), Amgen Inc. (\"Parent\") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share (\"Common Stock\"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not applicable."}],"balance_after":0,"derivative":{"exercise_price":6.09,"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-21-027417","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919121027417/doc4.xml","form_type":"4"}},{"id":2745452,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-04-19T19:46:08.000Z","date":"2021-04-16","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the \"Merger Agreement\"), by and among the Five Prime Therapeutics, Inc. (the \"Company\"), Amgen Inc. (\"Parent\") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share (\"Common Stock\"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the \"Merger Agreement\"), by and among the Five Prime Therapeutics, Inc. (the \"Company\"), Amgen Inc. (\"Parent\") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share (\"Common Stock\"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not applicable."}],"balance_after":0,"derivative":{"exercise_price":17.27,"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-027417","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919121027417/doc4.xml","form_type":"4"}},{"id":2745451,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-04-19T19:46:08.000Z","date":"2021-04-16","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the \"Merger Agreement\"), by and among the Five Prime Therapeutics, Inc. (the \"Company\"), Amgen Inc. (\"Parent\") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share (\"Common Stock\"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the \"Merger Agreement\"), by and among the Five Prime Therapeutics, Inc. (the \"Company\"), Amgen Inc. (\"Parent\") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share (\"Common Stock\"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not applicable."}],"balance_after":0,"derivative":{"exercise_price":29.8,"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-027417","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919121027417/doc4.xml","form_type":"4"}},{"id":2745450,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-04-19T19:46:08.000Z","date":"2021-04-16","kind":"disposition_to_issuer","acquired":false,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the \"Merger Agreement\"), by and among the Five Prime Therapeutics, Inc. (the \"Company\"), Amgen Inc. (\"Parent\") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share (\"Common Stock\"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the \"Merger Agreement\"), by and among the Five Prime Therapeutics, Inc. (the \"Company\"), Amgen Inc. (\"Parent\") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share (\"Common Stock\"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not applicable."}],"balance_after":0,"derivative":{"exercise_price":22.15,"underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-21-027417","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919121027417/doc4.xml","form_type":"4"}},{"id":2745449,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-04-19T19:46:08.000Z","date":"2021-04-16","kind":"disposition_to_issuer","acquired":false,"shares":16600,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the \"Merger Agreement\"), by and among the Five Prime Therapeutics, Inc. (the \"Company\"), Amgen Inc. (\"Parent\") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share (\"Common Stock\"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the \"Merger Agreement\"), by and among the Five Prime Therapeutics, Inc. (the \"Company\"), Amgen Inc. (\"Parent\") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share (\"Common Stock\"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not applicable."}],"balance_after":0,"derivative":{"exercise_price":11.65,"underlying":"Common Stock","underlying_shares":16600},"source":{"system":"sec-edgar","filing":"0001209191-21-027417","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919121027417/doc4.xml","form_type":"4"}},{"id":2745448,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-19T19:46:08.000Z","date":"2021-04-05","kind":"gift","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-027417","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919121027417/doc4.xml","form_type":"4"}},{"id":2981600,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-11-13T12:17:24.000Z","date":"2020-11-11","kind":"exercise","acquired":false,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vested in its entirety on May 19, 2020."}],"balance_after":52408,"derivative":{"exercise_price":2.8,"expiration_date":"2030-04-18","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001209191-20-058235","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919120058235/doc4.xml","form_type":"4"}},{"id":2981599,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-11-13T12:17:24.000Z","date":"2020-11-11","kind":"exercise","acquired":false,"shares":52959,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vested in its entirety on April 19, 2020."}],"balance_after":0,"derivative":{"exercise_price":2.22,"expiration_date":"2030-03-18","underlying":"Common Stock","underlying_shares":52959},"source":{"system":"sec-edgar","filing":"0001209191-20-058235","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919120058235/doc4.xml","form_type":"4"}},{"id":2981598,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-13T12:17:24.000Z","date":"2020-11-11","kind":"sale","acquired":false,"shares":26000,"price":22.5,"value":585000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001209191-20-058235","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919120058235/doc4.xml","form_type":"4"}},{"id":2981597,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-13T12:17:24.000Z","date":"2020-11-11","kind":"exercise","acquired":true,"shares":26000,"price":2.8,"value":72800.0,"ownership":{"direct":true},"balance_after":36000,"source":{"system":"sec-edgar","filing":"0001209191-20-058235","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919120058235/doc4.xml","form_type":"4"}},{"id":2981596,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-13T12:17:24.000Z","date":"2020-11-11","kind":"sale","acquired":false,"shares":52959,"price":22.5,"value":1191577.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001209191-20-058235","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919120058235/doc4.xml","form_type":"4"}},{"id":2981595,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-13T12:17:24.000Z","date":"2020-11-11","kind":"exercise","acquired":true,"shares":52959,"price":2.22,"value":117568.98,"ownership":{"direct":true},"balance_after":62959,"source":{"system":"sec-edgar","filing":"0001209191-20-058235","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919120058235/doc4.xml","form_type":"4"}},{"id":3110445,"issuer":{"id":5216,"kind":"organization","name":"ASSEMBLY BIOSCIENCES, INC."},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-15T20:46:05.000Z","date":"2020-06-11","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 11, 2021 and (2) the date of the Issuer's 2021 annual meeting of stockholders."}],"balance_after":10000,"derivative":{"exercise_price":20.47,"expiration_date":"2030-06-11","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-20-036642","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1426800/000120919120036642/doc4.xml","form_type":"4"}},{"id":3110444,"issuer":{"id":5216,"kind":"organization","name":"ASSEMBLY BIOSCIENCES, INC."},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-15T20:46:05.000Z","date":"2020-02-28","kind":"gift","acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":17465,"source":{"system":"sec-edgar","filing":"0001209191-20-036642","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1426800/000120919120036642/doc4.xml","form_type":"4"}},{"id":3141061,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-05-20T16:14:39.000Z","date":"2020-05-19","kind":"grant","acquired":true,"shares":27769,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in its entirety on June 19, 2020, subject to the reporting person's continued service to Five Prime Therapeutics, Inc. through such vest date."}],"balance_after":27769,"derivative":{"exercise_price":4.47,"expiration_date":"2030-05-18","underlying":"Common Stock","underlying_shares":27769},"source":{"system":"sec-edgar","filing":"0001209191-20-030871","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919120030871/doc4.xml","form_type":"4"}},{"id":3173144,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-04-20T19:55:10.000Z","date":"2020-04-19","kind":"grant","acquired":true,"shares":78408,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in its entirety on May 19, 2020, subject to the reporting person's continued service to Five Prime Therapeutics, Inc. through such vest date."}],"balance_after":78408,"derivative":{"exercise_price":2.8,"expiration_date":"2030-04-18","underlying":"Common Stock","underlying_shares":78408},"source":{"system":"sec-edgar","filing":"0001209191-20-025176","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919120025176/doc4.xml","form_type":"4"}},{"id":3199475,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-03-20T15:26:50.000Z","date":"2020-03-19","kind":"grant","acquired":true,"shares":52959,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in its entirety on April 19, 2020, subject to the reporting person's continued service to Five Prime Therapeutics, Inc. through such vest date."}],"balance_after":52959,"derivative":{"exercise_price":2.22,"expiration_date":"2030-03-18","underlying":"Common Stock","underlying_shares":52959},"source":{"system":"sec-edgar","filing":"0001209191-20-020394","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919120020394/doc4.xml","form_type":"4"}},{"id":3252594,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2020-02-24T19:32:00.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":3000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001562180-20-001617","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1238325/000156218020001617/primarydocument.xml","form_type":"4"}},{"id":3252593,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-02-24T19:32:00.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":9.38,"expiration_date":"2029-06-03","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001562180-20-001617","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1238325/000156218020001617/primarydocument.xml","form_type":"4"}},{"id":3252592,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-02-24T19:32:00.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":9.95,"expiration_date":"2028-06-12","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001562180-20-001617","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1238325/000156218020001617/primarydocument.xml","form_type":"4"}},{"id":3252591,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-02-24T19:32:00.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":28.01,"expiration_date":"2027-06-12","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001562180-20-001617","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1238325/000156218020001617/primarydocument.xml","form_type":"4"}},{"id":3252590,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-02-24T19:32:00.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":10344,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":28.82,"expiration_date":"2026-06-20","underlying":"Common Stock","underlying_shares":10344},"source":{"system":"sec-edgar","filing":"0001562180-20-001617","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1238325/000156218020001617/primarydocument.xml","form_type":"4"}},{"id":3252589,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-02-24T19:32:00.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":8620,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2025-06-10","underlying":"Common Stock","underlying_shares":8620},"source":{"system":"sec-edgar","filing":"0001562180-20-001617","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1238325/000156218020001617/primarydocument.xml","form_type":"4"}},{"id":3252588,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-02-24T19:32:00.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":18275,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2024-06-05","underlying":"Common Stock","underlying_shares":18275},"source":{"system":"sec-edgar","filing":"0001562180-20-001617","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1238325/000156218020001617/primarydocument.xml","form_type":"4"}},{"id":3252587,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-24T19:32:00.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":6000,"price":18.75,"value":112500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-20-001617","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1238325/000156218020001617/primarydocument.xml","form_type":"4"}},{"id":3259844,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-02-20T20:26:30.000Z","date":"2020-02-19","kind":"grant","acquired":true,"shares":37998,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in its entirety on March 19, 2020, subject to the reporting person's continued service to Five Prime Therapeutics, Inc. through such vest date."}],"balance_after":37998,"derivative":{"exercise_price":5.23,"expiration_date":"2030-02-18","underlying":"Common Stock","underlying_shares":37998},"source":{"system":"sec-edgar","filing":"0001209191-20-011327","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919120011327/doc4.xml","form_type":"4"}},{"id":3306597,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-01-21T13:34:43.000Z","date":"2020-01-20","kind":"grant","acquired":true,"shares":40868,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in its entirety on February 19, 2020, subject to the reporting person's continued service to Five Prime Therapeutics, Inc. through such vest date."}],"balance_after":40868,"derivative":{"exercise_price":5.31,"expiration_date":"2030-01-19","underlying":"Common Stock","underlying_shares":40868},"source":{"system":"sec-edgar","filing":"0001209191-20-004227","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919120004227/doc4.xml","form_type":"4"}},{"id":3306596,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-01-21T13:33:22.000Z","date":"2020-01-20","kind":"grant","acquired":true,"shares":40868,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in its entirety on February 19, 2020, subject to the reporting person's continued service to Five Prime Therapeutics, Inc. through such vest date."}],"balance_after":40868,"derivative":{"exercise_price":5.31,"expiration_date":"2030-01-19","underlying":"Common Stock","underlying_shares":40868},"source":{"system":"sec-edgar","filing":"0001209191-20-004225","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919120004225/doc4.xml","form_type":"4"}},{"id":3334061,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-12-20T18:39:35.000Z","date":"2019-12-19","kind":"grant","acquired":true,"shares":49552,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in its entirety on January 19, 2020, subject to the reporting person's continued service to Five Prime Therapeutics, Inc. through such vest date."}],"balance_after":49552,"derivative":{"exercise_price":3.94,"expiration_date":"2029-12-18","underlying":"Common Stock","underlying_shares":49552},"source":{"system":"sec-edgar","filing":"0001209191-19-061649","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919119061649/doc4.xml","form_type":"4"}},{"id":3364494,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-11-20T12:44:25.000Z","date":"2019-11-19","kind":"grant","acquired":true,"shares":50367,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in its entirety on December 19, 2019, subject to the reporting person's continued service to Five Prime Therapeutics, Inc. through such vest date."}],"balance_after":50367,"derivative":{"exercise_price":3.23,"expiration_date":"2029-11-18","underlying":"Common Stock","underlying_shares":50367},"source":{"system":"sec-edgar","filing":"0001209191-19-057402","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919119057402/doc4.xml","form_type":"4"}},{"id":3390247,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-10-21T17:30:03.000Z","date":"2019-10-19","kind":"grant","acquired":true,"shares":46939,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in its entirety on November 19, 2019, subject to the reporting person's continued service to Five Prime Therapeutics, Inc. through such vest date."}],"balance_after":46939,"derivative":{"exercise_price":3.99,"expiration_date":"2029-10-18","underlying":"Common Stock","underlying_shares":46939},"source":{"system":"sec-edgar","filing":"0001209191-19-053725","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919119053725/doc4.xml","form_type":"4"}},{"id":3396102,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-10-08T19:30:55.000Z","date":"2019-10-05","kind":"grant","acquired":true,"shares":34451,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in its entirety on October 19, 2019, subject to the reporting person's continued service to Five Prime Therapeutics, Inc. through such vest date."}],"balance_after":34451,"derivative":{"exercise_price":3.79,"expiration_date":"2029-10-04","underlying":"Common Stock","underlying_shares":34451},"source":{"system":"sec-edgar","filing":"0001209191-19-052804","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919119052804/doc4.xml","form_type":"4"}},{"id":3489395,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-14T17:15:56.000Z","date":"2019-06-12","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each RSU represents a contingent right to receive one share of DERM common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSU, which was granted on June 12, 2018, fully vested on June 12, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each RSU represents a contingent right to receive one share of DERM common stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001562180-19-003528","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1238325/000156218019003528/primarydocument.xml","form_type":"4"}},{"id":3489394,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-14T17:15:56.000Z","date":"2019-06-12","kind":"exercise","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001562180-19-003528","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1238325/000156218019003528/primarydocument.xml","form_type":"4"}},{"id":3492938,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-12T18:23:31.000Z","date":"2019-06-10","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in its entirety on the earlier to occur of (i) June 10, 2020 or (ii) the day before the 2020 annual meeting of stockholders of Five Prime Therapeutics, Inc. (the \"Company\"), subject to the reporting person's continued service to the Company through such vest date."}],"balance_after":15000,"derivative":{"exercise_price":6.09,"expiration_date":"2029-06-09","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-19-036508","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919119036508/doc4.xml","form_type":"4"}},{"id":3498631,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2019-06-06T20:15:47.000Z","date":"2019-06-04","kind":"grant","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of DERM common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSU will vest 100% of the shares on June 4, 2020, subject to the continuing service of the Reporting Person on such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each RSU represents a contingent right to receive one share of DERM common stock."}],"balance_after":3000,"derivative":{"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001562180-19-003406","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1238325/000156218019003406/primarydocument.xml","form_type":"4"}},{"id":3498630,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2019-06-06T20:15:47.000Z","date":"2019-06-04","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest and become exercisable as to 100% of the shares on June 4, 2020, subject to the continuing service of the Reporting Person on such vesting date."}],"balance_after":6000,"derivative":{"exercise_price":9.38,"expiration_date":"2029-06-03","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001562180-19-003406","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1238325/000156218019003406/primarydocument.xml","form_type":"4"}},{"id":3520657,"issuer":{"id":5216,"kind":"organization","name":"ASSEMBLY BIOSCIENCES, INC."},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-05-17T23:37:36.000Z","date":"2019-05-17","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the option will vest upon the earlier of (i) May 17, 2020 and (ii) the date of the Issuer's 2020 annual meeting of stockholders."}],"balance_after":10000,"derivative":{"exercise_price":15.22,"expiration_date":"2029-05-17","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001144204-19-027162","document":"tv521928_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1426800/000114420419027162/tv521928_4.xml","form_type":"4"}},{"id":3562568,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Rt to Buy)","published_at":"2019-04-04T17:10:00.000Z","date":"2019-04-02","kind":"disposition_to_issuer","acquired":false,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated February 20, 2019, by and among the Immune Design Corp. (the \"Issuer\"), Merck Sharp & Dohme Corp., a New Jersey corporation (\"Parent\") and Cascade Merger Sub Inc., a Delaware corporation (\"Purchaser\"), on April 2, 2019, Purchaser merged with and into the Issuer (the \"Merger\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated February 20, 2019, by and among the Immune Design Corp. (the \"Issuer\"), Merck Sharp & Dohme Corp., a New Jersey corporation (\"Parent\") and Cascade Merger Sub Inc., a Delaware corporation (\"Purchaser\"), on April 2, 2019, Purchaser merged with and into the Issuer (the \"Merger\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not Applicable."}],"balance_after":0,"derivative":{"exercise_price":1.31,"underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-19-023680","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1437786/000120919119023680/doc4.xml","form_type":"4"}},{"id":3562567,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Rt to Buy)","published_at":"2019-04-04T17:10:00.000Z","date":"2019-04-02","kind":"disposition_to_issuer","acquired":false,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated February 20, 2019, by and among the Immune Design Corp. (the \"Issuer\"), Merck Sharp & Dohme Corp., a New Jersey corporation (\"Parent\") and Cascade Merger Sub Inc., a Delaware corporation (\"Purchaser\"), on April 2, 2019, Purchaser merged with and into the Issuer (the \"Merger\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated February 20, 2019, by and among the Immune Design Corp. (the \"Issuer\"), Merck Sharp & Dohme Corp., a New Jersey corporation (\"Parent\") and Cascade Merger Sub Inc., a Delaware corporation (\"Purchaser\"), on April 2, 2019, Purchaser merged with and into the Issuer (the \"Merger\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not Applicable."}],"balance_after":0,"derivative":{"exercise_price":4.05,"underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-19-023680","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1437786/000120919119023680/doc4.xml","form_type":"4"}},{"id":3562566,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Rt to Buy)","published_at":"2019-04-04T17:10:00.000Z","date":"2019-04-02","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated February 20, 2019, by and among the Immune Design Corp. (the \"Issuer\"), Merck Sharp & Dohme Corp., a New Jersey corporation (\"Parent\") and Cascade Merger Sub Inc., a Delaware corporation (\"Purchaser\"), on April 2, 2019, Purchaser merged with and into the Issuer (the \"Merger\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated February 20, 2019, by and among the Immune Design Corp. (the \"Issuer\"), Merck Sharp & Dohme Corp., a New Jersey corporation (\"Parent\") and Cascade Merger Sub Inc., a Delaware corporation (\"Purchaser\"), on April 2, 2019, Purchaser merged with and into the Issuer (the \"Merger\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Not Applicable."}],"balance_after":0,"derivative":{"exercise_price":5.6,"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-19-023680","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437786/000120919119023680/doc4.xml","form_type":"4"}},{"id":3697491,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-01-11T18:07:58.000Z","date":"2019-01-09","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of restricted stock, which will vest in their entirety on January 9, 2020, provided the reporting person provides services to Five Prime Therapeutics, Inc. through such date."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001209191-19-003458","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919119003458/doc4.xml","form_type":"4"}},{"id":3701868,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-01-07T20:18:17.000Z","date":"2019-01-03","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares underlying the option will vest on January 3, 2020."}],"balance_after":12500,"derivative":{"exercise_price":1.31,"expiration_date":"2029-01-03","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-19-002660","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437786/000120919119002660/doc4.xml","form_type":"4"}},{"id":3874786,"issuer":{"id":5216,"kind":"organization","name":"ASSEMBLY BIOSCIENCES, INC."},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-07-03T20:00:40.000Z","date":"2018-07-02","kind":"exercise","acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option, initially representing a right to purchase 64,000 shares, became exercisable in three equal installments on July 11, 2014; July 11, 2015; and July 11, 2016."}],"balance_after":49000,"derivative":{"exercise_price":7.2,"expiration_date":"2024-07-10","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001144204-18-037217","document":"v497988_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1426800/000114420418037217/v497988_4.xml","form_type":"4"}},{"id":3874785,"issuer":{"id":5216,"kind":"organization","name":"ASSEMBLY BIOSCIENCES, INC."},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-07-03T20:00:40.000Z","date":"2018-07-02","kind":"sale","acquired":false,"shares":1000,"price":38.503,"value":38503.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.50 to $38.515, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within."}],"balance_after":19465,"source":{"system":"sec-edgar","filing":"0001144204-18-037217","document":"v497988_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1426800/000114420418037217/v497988_4.xml","form_type":"4"}},{"id":3874784,"issuer":{"id":5216,"kind":"organization","name":"ASSEMBLY BIOSCIENCES, INC."},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-07-03T20:00:40.000Z","date":"2018-07-02","kind":"exercise","acquired":true,"shares":1000,"price":7.2,"value":7200.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":20465,"source":{"system":"sec-edgar","filing":"0001144204-18-037217","document":"v497988_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1426800/000114420418037217/v497988_4.xml","form_type":"4"}},{"id":3893613,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2018-06-14T17:45:34.000Z","date":"2018-06-13","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of DERM common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSU, which was granted on June 13, 2017, fully vested on June 13, 2018."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each RSU represents a contingent right to receive one share of DERM common stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001562180-18-003001","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1238325/000156218018003001/primarydocument.xml","form_type":"4"}},{"id":3893612,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2018-06-14T17:45:34.000Z","date":"2018-06-12","kind":"grant","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of DERM common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSU will vest 100% of the shares on June 12, 2019, subject to the continuing service of the Reporting Person on such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each RSU represents a contingent right to receive one share of DERM common stock."}],"balance_after":3000,"derivative":{"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001562180-18-003001","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1238325/000156218018003001/primarydocument.xml","form_type":"4"}},{"id":3893611,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2018-06-14T17:45:34.000Z","date":"2018-06-12","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option will vest and become exercisable as to 100% of the shares on June 12, 2019, subject to the continuing service of the Reporting Person on such vesting date."}],"balance_after":6000,"derivative":{"exercise_price":9.95,"expiration_date":"2028-06-12","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001562180-18-003001","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1238325/000156218018003001/primarydocument.xml","form_type":"4"}},{"id":3893610,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-14T17:45:34.000Z","date":"2018-06-13","kind":"exercise","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Represents shares acquired upon vesting of RSU granted on June 13, 2017."}],"balance_after":3000,"source":{"system":"sec-edgar","filing":"0001562180-18-003001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1238325/000156218018003001/primarydocument.xml","form_type":"4"}},{"id":3910597,"issuer":{"id":5216,"kind":"organization","name":"ASSEMBLY BIOSCIENCES, INC."},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-01T21:54:13.000Z","date":"2018-06-01","kind":"exercise","acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option, initially representing a right to purchase 64,000 shares, became exercisable in three equal installments on July 11, 2014; July 11, 2015; and July 11, 2016."}],"balance_after":50000,"derivative":{"exercise_price":7.2,"expiration_date":"2024-07-10","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001144204-18-032476","document":"tv495701_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1426800/000114420418032476/tv495701_4.xml","form_type":"4"}},{"id":3910596,"issuer":{"id":5216,"kind":"organization","name":"ASSEMBLY BIOSCIENCES, INC."},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-01T21:54:13.000Z","date":"2018-05-30","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares of common stock underlying the option will vest upon the earlier of (i) May 30, 2019 and (ii) the date of the Issuer's 2019 annual meeting of stockholders."}],"balance_after":7500,"derivative":{"exercise_price":42.09,"expiration_date":"2028-05-30","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001144204-18-032476","document":"tv495701_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1426800/000114420418032476/tv495701_4.xml","form_type":"4"}},{"id":3910595,"issuer":{"id":5216,"kind":"organization","name":"ASSEMBLY BIOSCIENCES, INC."},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-01T21:54:13.000Z","date":"2018-06-01","kind":"sale","acquired":false,"shares":1000,"price":42.47,"value":42470.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":19465,"source":{"system":"sec-edgar","filing":"0001144204-18-032476","document":"tv495701_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1426800/000114420418032476/tv495701_4.xml","form_type":"4"}},{"id":3910594,"issuer":{"id":5216,"kind":"organization","name":"ASSEMBLY BIOSCIENCES, INC."},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-01T21:54:13.000Z","date":"2018-06-01","kind":"exercise","acquired":true,"shares":1000,"price":7.2,"value":7200.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":20465,"source":{"system":"sec-edgar","filing":"0001144204-18-032476","document":"tv495701_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1426800/000114420418032476/tv495701_4.xml","form_type":"4"}},{"id":3935002,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-05-14T20:23:44.000Z","date":"2018-05-10","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in its entirety on the earlier to occur of (i) May 10, 2019 or (ii) the day before the 2019 annual meeting of stockholders of Five Prime Therapeutics, Inc. (the \"Company\"), subject to the reporting person's continued service to the Company through such vest date."}],"balance_after":10000,"derivative":{"exercise_price":17.27,"expiration_date":"2028-05-09","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-18-030084","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919118030084/doc4.xml","form_type":"4"}},{"id":3949680,"issuer":{"id":5216,"kind":"organization","name":"ASSEMBLY BIOSCIENCES, INC."},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-05-02T20:05:35.000Z","date":"2018-05-01","kind":"exercise","acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option, initially representing a right to purchase 64,000 shares, became exercisable in three equal installments on July 11, 2014; July 11, 2015; and July 11, 2016."}],"balance_after":51000,"derivative":{"exercise_price":7.2,"expiration_date":"2024-07-10","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001144204-18-024758","document":"tv492751_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1426800/000114420418024758/tv492751_4.xml","form_type":"4"}},{"id":3949679,"issuer":{"id":5216,"kind":"organization","name":"ASSEMBLY BIOSCIENCES, INC."},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-05-02T20:05:35.000Z","date":"2018-05-01","kind":"sale","acquired":false,"shares":1000,"price":43.06,"value":43060.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":19465,"source":{"system":"sec-edgar","filing":"0001144204-18-024758","document":"tv492751_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1426800/000114420418024758/tv492751_4.xml","form_type":"4"}},{"id":3949678,"issuer":{"id":5216,"kind":"organization","name":"ASSEMBLY BIOSCIENCES, INC."},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-05-02T20:05:35.000Z","date":"2018-05-01","kind":"exercise","acquired":true,"shares":1000,"price":7.2,"value":7200.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":20465,"source":{"system":"sec-edgar","filing":"0001144204-18-024758","document":"tv492751_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1426800/000114420418024758/tv492751_4.xml","form_type":"4"}},{"id":3976329,"issuer":{"id":5216,"kind":"organization","name":"ASSEMBLY BIOSCIENCES, INC."},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-04-02T22:07:27.000Z","date":"2018-04-02","kind":"exercise","acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option, initially representing a right to purchase 64,000 shares, became exercisable in three equal installments on July 11, 2014; July 11, 2015; and July 11, 2016."}],"balance_after":52000,"derivative":{"exercise_price":7.2,"expiration_date":"2024-07-10","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001144204-18-018748","document":"tv490129_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1426800/000114420418018748/tv490129_form4.xml","form_type":"4"}},{"id":3976328,"issuer":{"id":5216,"kind":"organization","name":"ASSEMBLY BIOSCIENCES, INC."},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-04-02T22:07:27.000Z","date":"2018-04-02","kind":"sale","acquired":false,"shares":1000,"price":49.32,"value":49320.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":19465,"source":{"system":"sec-edgar","filing":"0001144204-18-018748","document":"tv490129_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1426800/000114420418018748/tv490129_form4.xml","form_type":"4"}},{"id":3976327,"issuer":{"id":5216,"kind":"organization","name":"ASSEMBLY BIOSCIENCES, INC."},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-04-02T22:07:27.000Z","date":"2018-04-02","kind":"exercise","acquired":true,"shares":1000,"price":7.2,"value":7200.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":20465,"source":{"system":"sec-edgar","filing":"0001144204-18-018748","document":"tv490129_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1426800/000114420418018748/tv490129_form4.xml","form_type":"4"}},{"id":4019757,"issuer":{"id":5216,"kind":"organization","name":"ASSEMBLY BIOSCIENCES, INC."},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-03-02T21:01:53.000Z","date":"2018-03-01","kind":"exercise","acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option, initially representing a right to purchase 64,000 shares, became exercisable in three equal installments on July 11, 2014; July 11, 2015; and July 11, 2016."}],"balance_after":53000,"derivative":{"exercise_price":7.2,"expiration_date":"2024-07-10","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001144204-18-012524","document":"tv487549_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1426800/000114420418012524/tv487549_4.xml","form_type":"4"}},{"id":4019756,"issuer":{"id":5216,"kind":"organization","name":"ASSEMBLY BIOSCIENCES, INC."},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-02T21:01:53.000Z","date":"2018-03-01","kind":"sale","acquired":false,"shares":1000,"price":56.37,"value":56370.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":19465,"source":{"system":"sec-edgar","filing":"0001144204-18-012524","document":"tv487549_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1426800/000114420418012524/tv487549_4.xml","form_type":"4"}},{"id":4019755,"issuer":{"id":5216,"kind":"organization","name":"ASSEMBLY BIOSCIENCES, INC."},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-02T21:01:53.000Z","date":"2018-03-01","kind":"exercise","acquired":true,"shares":1000,"price":7.2,"value":7200.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":20465,"source":{"system":"sec-edgar","filing":"0001144204-18-012524","document":"tv487549_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1426800/000114420418012524/tv487549_4.xml","form_type":"4"}},{"id":4079057,"issuer":{"id":5216,"kind":"organization","name":"ASSEMBLY BIOSCIENCES, INC."},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-02-02T21:05:19.000Z","date":"2018-02-01","kind":"exercise","acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option, initially representing a right to purchase 64,000 shares, became exercisable in three equal installments on July 11, 2014; July 11, 2015; and July 11, 2016."}],"balance_after":54000,"derivative":{"exercise_price":7.2,"expiration_date":"2024-07-10","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001144204-18-005474","document":"tv484793_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1426800/000114420418005474/tv484793_4.xml","form_type":"4"}},{"id":4079056,"issuer":{"id":5216,"kind":"organization","name":"ASSEMBLY BIOSCIENCES, INC."},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-02-02T21:05:19.000Z","date":"2018-02-01","kind":"sale","acquired":false,"shares":1000,"price":46.86,"value":46860.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":19465,"source":{"system":"sec-edgar","filing":"0001144204-18-005474","document":"tv484793_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1426800/000114420418005474/tv484793_4.xml","form_type":"4"}},{"id":4079055,"issuer":{"id":5216,"kind":"organization","name":"ASSEMBLY BIOSCIENCES, INC."},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-02-02T21:05:19.000Z","date":"2018-02-01","kind":"exercise","acquired":true,"shares":1000,"price":7.2,"value":7200.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":20465,"source":{"system":"sec-edgar","filing":"0001144204-18-005474","document":"tv484793_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1426800/000114420418005474/tv484793_4.xml","form_type":"4"}},{"id":4104189,"issuer":{"id":158527,"kind":"organization","name":"IMMUNE DESIGN CORP.","symbol":"IMDZ"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-01-08T20:31:42.000Z","date":"2018-01-04","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares underlying the option will vest on January 4, 2019."}],"balance_after":12500,"derivative":{"exercise_price":4.05,"expiration_date":"2028-01-04","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-18-002817","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437786/000120919118002817/doc4.xml","form_type":"4"}},{"id":4111466,"issuer":{"id":5216,"kind":"organization","name":"ASSEMBLY BIOSCIENCES, INC."},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-01-03T21:30:46.000Z","date":"2018-01-02","kind":"exercise","acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option, initially representing a right to purchase 64,000 shares, became exercisable in three equal installments on July 11, 2014; July 11, 2015; and July 11, 2016."}],"balance_after":55000,"derivative":{"exercise_price":7.2,"expiration_date":"2024-07-10","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001144204-18-000532","document":"tv482455_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1426800/000114420418000532/tv482455_4.xml","form_type":"4"}},{"id":4111465,"issuer":{"id":5216,"kind":"organization","name":"ASSEMBLY BIOSCIENCES, INC."},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-03T21:30:46.000Z","date":"2018-01-02","kind":"sale","acquired":false,"shares":1000,"price":45.04,"value":45040.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":19465,"source":{"system":"sec-edgar","filing":"0001144204-18-000532","document":"tv482455_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1426800/000114420418000532/tv482455_4.xml","form_type":"4"}},{"id":4111464,"issuer":{"id":5216,"kind":"organization","name":"ASSEMBLY BIOSCIENCES, INC."},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-03T21:30:46.000Z","date":"2018-01-02","kind":"exercise","acquired":true,"shares":1000,"price":7.2,"value":7200.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":20465,"source":{"system":"sec-edgar","filing":"0001144204-18-000532","document":"tv482455_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1426800/000114420418000532/tv482455_4.xml","form_type":"4"}},{"id":4144185,"issuer":{"id":5216,"kind":"organization","name":"ASSEMBLY BIOSCIENCES, INC."},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-12-04T21:05:32.000Z","date":"2017-12-01","kind":"exercise","acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option, initially representing a right to purchase 64,000 shares, became exercisable in three equal installments on July 11, 2014; July 11, 2015; and July 11, 2016."}],"balance_after":56000,"derivative":{"exercise_price":7.2,"expiration_date":"2024-07-10","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001144204-17-062200","document":"tv480756_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1426800/000114420417062200/tv480756_form4.xml","form_type":"4"}},{"id":4144184,"issuer":{"id":5216,"kind":"organization","name":"ASSEMBLY BIOSCIENCES, INC."},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-12-04T21:05:32.000Z","date":"2017-12-01","kind":"sale","acquired":false,"shares":1000,"price":49.37,"value":49370.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":19465,"source":{"system":"sec-edgar","filing":"0001144204-17-062200","document":"tv480756_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1426800/000114420417062200/tv480756_form4.xml","form_type":"4"}},{"id":4144183,"issuer":{"id":5216,"kind":"organization","name":"ASSEMBLY BIOSCIENCES, INC."},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-12-04T21:05:32.000Z","date":"2017-12-01","kind":"exercise","acquired":true,"shares":1000,"price":7.2,"value":7200.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":20465,"source":{"system":"sec-edgar","filing":"0001144204-17-062200","document":"tv480756_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1426800/000114420417062200/tv480756_form4.xml","form_type":"4"}},{"id":4172660,"issuer":{"id":5216,"kind":"organization","name":"ASSEMBLY BIOSCIENCES, INC."},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-11-03T21:15:25.000Z","date":"2017-11-01","kind":"exercise","acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option, initially representing a right to purchase 64,000 shares, became exercisable in three equal installments on July 11, 2014; July 11, 2015; and July 11, 2016."}],"balance_after":57000,"derivative":{"exercise_price":7.2,"expiration_date":"2024-07-10","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001144204-17-056293","document":"tv478456_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1426800/000114420417056293/tv478456_4.xml","form_type":"4"}},{"id":4172659,"issuer":{"id":5216,"kind":"organization","name":"ASSEMBLY BIOSCIENCES, INC."},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-11-03T21:15:25.000Z","date":"2017-11-01","kind":"sale","acquired":false,"shares":1000,"price":29.55,"value":29550.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.36 to $29.75, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within."}],"balance_after":19465,"source":{"system":"sec-edgar","filing":"0001144204-17-056293","document":"tv478456_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1426800/000114420417056293/tv478456_4.xml","form_type":"4"}},{"id":4172658,"issuer":{"id":5216,"kind":"organization","name":"ASSEMBLY BIOSCIENCES, INC."},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-11-03T21:15:25.000Z","date":"2017-11-01","kind":"exercise","acquired":true,"shares":1000,"price":7.2,"value":7200.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":20465,"source":{"system":"sec-edgar","filing":"0001144204-17-056293","document":"tv478456_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1426800/000114420417056293/tv478456_4.xml","form_type":"4"}},{"id":4174763,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-11-02T14:13:10.000Z","date":"2017-11-01","kind":"exercise","acquired":false,"shares":600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option is fully vested and immediately exercisable."}],"balance_after":16600,"derivative":{"exercise_price":11.65,"expiration_date":"2024-09-30","underlying":"Common Stock","underlying_shares":600},"source":{"system":"sec-edgar","filing":"0001209191-17-058761","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919117058761/doc4.xml","form_type":"4"}},{"id":4174762,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-11-02T14:13:10.000Z","date":"2017-11-01","kind":"sale","acquired":false,"shares":600,"price":45.33,"value":27198.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on April 15, 2016."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-17-058761","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919117058761/doc4.xml","form_type":"4"}},{"id":4174761,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":16993,"kind":"person","name":"RINGO WILLIAM R","position":1,"cik":"0001238325","reported_name":"RINGO WILLIAM R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-11-02T14:13:10.000Z","date":"2017-11-01","kind":"exercise","acquired":true,"shares":600,"price":11.65,"value":6990.0,"ownership":{"direct":true},"balance_after":600,"source":{"system":"sec-edgar","filing":"0001209191-17-058761","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919117058761/doc4.xml","form_type":"4"}}],"next_cursor":"2017-11-02T14:13:10.000000Z,4174761"}